3 Cardiac and Chronic Care Drug Maker, Powertrain Components Maker and Digital Engineering Firm Stocks With a Strong Future Roadmap: Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies

Cardiac drug, powertrain and digital stocks let investors follow companies that serve a growing part of the Indian economy. Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies cover a cardiac and chronic care drug maker, a powertrain components maker and a digital engineering firm.

This list covers three cardiac drug, powertrain and digital stocks with complete current figures: Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Every figure comes from the latest reported financials and the 4 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Cardiac Drug, Powertrain and Digital Stocks?

Cardiac drug, powertrain and digital stocks are listed companies that sell cardiac and chronic care medicines, make powertrain and aluminium components for vehicles and industry, and provide digital engineering and cloud services to global clients. Their earnings depend on prescriptions, vehicle output and client technology budgets.

Cardiac Drug, Powertrain and Digital Stocks at a Glance

On valuation, Zensar Technologies trades at a P/E below the industry P/E, while Torrent Pharmaceuticals and Craftsman Automation trade above it, which reflects the growth the market already expects. Readers comparing cardiac drug, powertrain and digital stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in cardiac drug, powertrain and digital stocks can use the coming numbers to test whether growth is holding.

Why Do Cardiac Drug, Powertrain and Digital Stocks Have a Strong Roadmap in India?

Cardiac drug, powertrain and digital stocks have a strong roadmap in India because rising chronic care medicine use, steady vehicle output and growing client technology spending keep widening the market for these companies.

• Cardiac drugs. Chronic care medicines see steady use.
• Powertrain parts. Vehicle makers need dependable components.
• Digital services. Global clients modernise systems.

Why Torrent Pharmaceuticals Features Among These Cardiac Drug, Powertrain and Digital Stocks

Among the cardiac drug, powertrain and digital stocks on this list, Torrent Pharmaceuticals is an Ahmedabad-based pharma company that leads in cardiovascular, central nervous system and gastro-intestinal therapies in India, with a growing presence in Brazil, Germany and the United States.

Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%.

In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0.

Roadmap: The company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

What to watch: Watch the integration of newly acquired brands and the progress of margin improvement in the enlarged business.

Why Craftsman Automation Features Among These Cardiac Drug, Powertrain and Digital Stocks

Among the pharma, auto part and technology shares on this list, Craftsman Automation, based in Coimbatore, makes powertrain components, aluminium products and industrial and engineering products such as storage solutions and machine building.

In the June 2026 quarter, revenue grew 37.2% year on year to Rs 2,455 crore, while net profit rose 116.3% to Rs 151 crore. Revenue rose from Rs 2,224 crore in FY22 to Rs 8,131 crore in FY26, a compound annual growth rate of 38.3%.

Net profit grew from Rs 163 crore in FY22 to Rs 384 crore in FY26, which works out to a compound annual growth rate of 23.9%. The company has a return on equity of 11.8%, a debt to equity ratio of 1.11 and a market capitalisation of Rs 28,768 crore. The stock trades at a P/E of 61.9, above the industry P/E of 36.1.

Roadmap: The company is adding capacity across powertrain, aluminium and industrial divisions to serve customers in several sectors. A diversified base reduces dependence on any one product line.

What to watch: Follow capacity additions, aluminium division growth and demand from industrial customers.

Why Zensar Technologies Features Among These Cardiac Drug, Powertrain and Digital Stocks

Among the three companies on this list, Zensar Technologies, an RPG group company, offers digital engineering, cloud and experience services to clients across financial services, retail and manufacturing.

The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 15.1, below the industry P/E of 17.5.

Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore.

Roadmap: Strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.

What to watch: Follow client concentration and growth in large accounts.

Torrent Pharmaceuticals vs Craftsman Automation vs Zensar Technologies on Key Financials

The table below sets the three cardiac drug, powertrain and digital stocks side by side on revenue, profit and margin, using reported figures.

Torrent Pharmaceuticals posts the highest return on equity in this group at 25.5%. Torrent Pharmaceuticals has the largest FY26 revenue at Rs 13,886 crore, and Craftsman Automation shows the fastest revenue growth with a 38.3% compound annual rate. A useful habit with cardiac drug, powertrain and digital stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Cardiac Drug, Powertrain and Digital Stocks

Every theme carries risks that deserve a check before any decision. For these cardiac drug, powertrain and digital stocks, the main points are: Long-term pharma, auto part and technology shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Client spending. Technology budgets can vary with global conditions.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter cardiac drug, powertrain and digital stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Cardiac Drug, Powertrain and Digital Stocks

Cardiac drug, powertrain and digital stocks reward investors who follow demand trends, order books and margins together. Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies each have a clear plan to grow. Based on the 4 November 2026 close, Torrent Pharmaceuticals trades at Rs 4,738.5, Craftsman Automation at Rs 10,685 and Zensar Technologies at Rs 533. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these cardiac drug, powertrain and digital stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track cardiac drug, powertrain and digital stocks, set price alerts and get research-backed stock ideas.

What are cardiac drug, powertrain and digital stocks?

Ans. Cardiac drug, powertrain and digital stocks are listed companies that sell cardiac and chronic care medicines, make powertrain and aluminium components for vehicles and industry, and provide digital engineering and cloud services to global clients. Their earnings depend on prescriptions, vehicle output and client technology budgets. This list looks at three of them, Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies, using reported FY22 to FY26 financials and the 4 November 2026 closing prices.

Which cardiac drug, powertrain and digital stocks are covered in this list?

Ans. This list covers Torrent Pharmaceuticals, Craftsman Automation and Zensar Technologies. Based on the 4 November 2026 close, Torrent Pharmaceuticals traded at Rs 4,738.5, Craftsman Automation at Rs 10,685 and Zensar Technologies at Rs 533. Their return on equity ranges from 11.8% to 25.5%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.8% to 38.3%.

Why do cardiac drug, powertrain and digital stocks have a strong future roadmap in India?

Ans. Cardiac drug, powertrain and digital stocks have a strong roadmap in India because rising chronic care medicine use, steady vehicle output and growing client technology spending keep widening the market for these companies. The main drivers are as follows. Cardiac drugs. Chronic care medicines see steady use. Powertrain parts. Vehicle makers need dependable components. Digital services. Global clients modernise systems. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Torrent Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 8,705 crore in FY22 to Rs 13,886 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 777 crore in FY22 to Rs 2,138 crore in FY26, which works out to a compound annual growth rate of 28.8%. In the June 2026 quarter, revenue grew 56.3% year on year to Rs 4,909 crore, while net profit rose 3.3% to Rs 566 crore. The company has a return on equity of 25.5%, a debt to equity ratio of 1.79 and a market capitalisation of Rs 173,079 crore. The stock trades at a P/E of 80.3, above the industry P/E of 36.0. Looking ahead, the company has strengthened its domestic position through acquisition of established brands and focuses on chronic therapies, where repeat prescriptions support sales. Its overseas markets contribute a steady share of revenue and add geographic balance.

How has Craftsman Automation performed financially?

Ans. Revenue rose from Rs 2,224 crore in FY22 to Rs 8,131 crore in FY26, a compound annual growth rate of 38.3%. Net profit grew from Rs 163 crore in FY22 to Rs 384 crore in FY26, which works out to a compound annual growth rate of 23.9%. In the June 2026 quarter, revenue grew 37.2% year on year to Rs 2,455 crore, while net profit rose 116.3% to Rs 151 crore. The company has a return on equity of 11.8%, a debt to equity ratio of 1.11 and a market capitalisation of Rs 28,768 crore. The stock trades at a P/E of 61.9, above the industry P/E of 36.1. Looking ahead, the company is adding capacity across powertrain, aluminium and industrial divisions to serve customers in several sectors. A diversified base reduces dependence on any one product line.

How has Zensar Technologies performed financially?

Ans. Revenue rose from Rs 4,382 crore in FY22 to Rs 5,921 crore in FY26, a compound annual growth rate of 7.8%. Net profit grew from Rs 422 crore in FY22 to Rs 775 crore in FY26, which works out to a compound annual growth rate of 16.4%. In the June 2026 quarter, revenue grew 8.6% year on year to Rs 1,566 crore, while net profit rose 1.0% to Rs 184 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 11,686 crore. The stock trades at a P/E of 15.1, below the industry P/E of 17.5. Looking ahead, strong deal wins in cloud and data work, a focus on fewer, larger clients and the use of artificial intelligence in delivery support its path. Cost discipline has allowed margins to improve over the years.

What risks should investors check before buying cardiac drug, powertrain and digital stocks?

Ans. Investors should check a few risks before buying cardiac drug, powertrain and digital stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of cardiac drug, powertrain and digital stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 4 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.